Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

NCT00310817 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

623

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Meningitis

Interventions

BIOLOGICAL: MenACWY-CRM conjugate vaccine, adjuvanted
BIOLOGICAL: MenACWY polysaccharide vaccine
BIOLOGICAL: MenACWY-CRM conjugate vaccine, unadjuvanted

Sponsor

Novartis Vaccines

Collaborators

[object Object]